Generic Medicines: Definition, Contents, And Development Timeline.pdf

## Questions and Answers on Generic Medicines (EMA)

What is a generic medicine?

A generic medicine is identical to a previously approved ("reference") medicine in terms of:

Active substance(s)
Dose(s)
Treatment for

While it may look different (name, color, shape, packaging), its medical effect is the same.

When can a generic medicine be developed?

Generic medicines can only be developed and marketed after the exclusivity period of the reference medicine has expired. This typically lasts 10 years from the date of first authorization. Patent protection for specific uses (not just the active ingredient) can extend this timeline.

What are hybrid medicines?

Hybrid medicines are generic versions that differ from the reference medicine in:

Strength
Route of administration
Indication (limited use without prescription)

They require both data from original trials on the reference medicine and new data to gain authorization.

How are generic medicines evaluated for safety and efficacy?

Generic medicines undergo a scientific evaluation by regulatory authorities, like the EMA:

Quality: Ensuring the medicine meets quality standards.
Bioequivalence: Proving it delivers the same levels of active substance as the reference medicine (required for orally absorbed medicines).
Clinical trials: May be needed for hybrid medicines or if a different salt form is used.

How are generic medicines authorized?

Authorization is granted after successful evaluation demonstrating:

Efficacy (from clinical studies)
Safety
Quality

The product information (labeling, packaging leaflet) of generic medicines mirrors that of the reference medicine, except for differences in excipients and patented indications.